This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Is Charles River (CRL) a Solid Growth Stock? 3 Reasons to Think " Yes "
by Zacks Equity Research
Charles River (CRL) could produce exceptional returns because of its solid growth attributes.
Abbott's (ABT) Diabetes Arm Booms, Neuromodulation Sales Soft
by Zacks Equity Research
Even though COVID-19 case rates are surging in the United States and other geographies, Abbott is seeing growth in its consumer-facing businesses like nutrition, EPD and diabetes care.
Here's Why You Should Hold on to Tandem Diabetes (TNDM) for Now
by Zacks Equity Research
Investors are optimistic about Tandem Diabetes' (TNDM) t:slim X2 technology and greater use of Control-IQ technology.
3 Reasons Why Charles River (CRL) Is a Great Growth Stock
by Zacks Equity Research
Charles River (CRL) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?
by Zacks Equity Research
Sector ETF report for FBT
Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FBT
Here's Why You Should Retain Charles River (CRL) Stock for Now
by Zacks Equity Research
Investors are optimistic about Charles River (CRL) on acquisitions of Cognate BioServices and Vigene Biosciences.
Charles River (CRL) Down 3.5% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Charles River (CRL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Charles River (CRL) Q3 Earnings Beat Estimates, EPS View Up
by Zacks Equity Research
Charles River (CRL) exited the third quarter of 2021 with better-than-expected earnings on strength in the RMS, DSA and Manufacturing Solutions arms driving the top line.
Charles River Laboratories (CRL) Q3 Earnings Top Estimates
by Zacks Equity Research
Charles River (CRL) delivered earnings and revenue surprises of 5.06% and -1.39%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?
by Zacks Equity Research
Sector ETF report for FBT
Charles River (CRL) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Robust demand for research models and the Vigene Biosciences buyout are likely to have contributed to growth for Charles River (CRL).
Charles River Laboratories (CRL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Charles River (CRL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FBT
Charles River (CRL) to Offer Cryo-EM Capabilities With New Pact
by Zacks Equity Research
Charles River's (CRL) recent partnership will enable the company to improve drug discovery projects by allowing structure-based design for a greater portfolio of targets.
Here's Why You Should Invest in Charles River (CRL) Now
by Zacks Equity Research
Investors are optimistic about Charles River (CRL) on solid second-quarter performance and bullish 2021 guidance.
Why Is Charles River (CRL) Up 9.5% Since Last Earnings Report?
by Zacks Equity Research
Charles River (CRL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Charles River (CRL) at a 52-Week High: What's Driving It?
by Zacks Equity Research
Charles River (CRL) ended the second quarter on a strong note with solid performance by the RMS, DSA and Manufacturing Support arms driving the top line.
MODV or CRL: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
MODV vs. CRL: Which Stock Is the Better Value Option?
Charles River (CRL) Q2 Earnings Beat Estimates, 2021 View Up
by Zacks Equity Research
Robust performance by all three segments drove Charles River's (CRL) revenues in the second quarter.
Charles River Laboratories (CRL) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Charles River (CRL) delivered earnings and revenue surprises of 9.21% and 5.17%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Charles River (CRL) Q2 Earnings to Mirror Broad-Based Demand
by Zacks Equity Research
Charles River's (CRL) biotech clients are likely to have benefited from a robust funding environment in Q2.
Charles River Laboratories (CRL) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Charles River (CRL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Charles River (CRL) at a 52-Week High: What's Driving It?
by Zacks Equity Research
Strong performance by the RMS, DSA and Manufacturing segments is driving the top line for Charles River (CRL).
10 Top-Ranked Stocks Powering S&P 500 ETF
by Sweta Killa
The S&P 500 has been outperforming this year due to the strength in value and cyclical stocks, which were battered last year in the pandemic.